Aripiprazole Oral Solution in the Treatment of Children and Adolescents With Autistic Disorder

Autistic Disorder Clinical Trial

Official title:

A Multicenter, Randomized, Double-blind, Flexible-dosed, Placebo-controlled, Parallel-group Clinical Trial Evaluating the Efficacy and Safety of Aripiprazole Oral Solution in Children and Adolescents With Autistic Disorder

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT03487770
• Other study ID #: 031-403-00106
• Status: Completed
• Phase: Phase 3
• Start date: April 9, 2018
• Est. completion date: April 21, 2020

Study information

• Verified date: January 2020
• Source: Otsuka Beijing Research Institute
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This is a multicenter, randomized, double-blind, placebo-controlled, parallel-group study to assess the efficacy, safety, tolerability and the steady-state plasma trough concentration of aripiprazole flexible-dosed in children and adolescents with a diagnosis of Autistic Disorder. Approximately 100 subjects will be randomly assigned at a 1:1 ratio to receive aripiprazole (2 to 15 mg) or placebo treatment for 8 weeks

Description:

Screening Phase: up to 42 days (consisting of a Screening Visit (V1), a washout period and Interim Screening Visit (V1a) when applicable, and a Baseline Visit (V2). The Screening Phase will serve multiple purposes: to allow for appropriate washout of prohibited medications; to allow for review of screening data; to establish a pre-treatment baseline of key outcome measures.

Treatment Phase: The duration of the treatment is 8 weeks. The purpose of the treatment phase is to evaluate the efficacy, safety, tolerability and steady-state plasma trough concentration of aripiprazole in the treatment of serious behavioral problems in children and adolescents with a diagnosis of Autistic Disorder..

Safety Follow-up Phase: All subjects will be followed up for safety (adverse events) at Day 16 after the last medication via telephone.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 111
• Est. completion date: April 21, 2020
• Est. primary completion date: April 21, 2020
• Accepts healthy volunteers: No
• Gender: All
• Age group: 6 Years to 17 Years

Eligibility

Inclusion Criteria:

1. Written informed consent must be obtained from a legally authorized guardianprior to the initiation of any protocol-required procedures.

2. The subject and/or the designated guardian(s) or caregiver(s) are able to comprehend and satisfactorily comply with the protocol requirements, in the opinion of the Investigator.

3. The patient meets current DSM-IV-TR diagnostic criteria for Autistic Disorder and also demonstrates behaviors such as tantrums, aggression, self-injurious behavior, or a combination of these problems. In addition, the Childhood Autism Rating Scale (CARS) score is =30.

4. The subject has a Clinical Global Impressions-Severity (CGI-S) score = 4 AND an ABC-I subscale score =18 at screening (Visit 1 or Visit 1a) and baseline (V2).

5. Environmental factors can be consistent throughout the trial period.

6. The subject is a male or female child or adolescent 6 to 17 years of age (6 = age = 17) at Baseline (V2).

Exclusion Criteria:

1. Women of childbearing potential (WOCBP) who are unwilling or unable to use an acceptable method to avoid pregnancy for the entire study period and for up to 8 weeks after the study.

Note: WOCBP include any female who has experienced menarche and who has not undergone successful surgical sterilization (hysterectomy, bilateral tubal ligation or bilateral oophorectomy) or is not postmenopausal [defined as amenorrhea 12 consecutive months; or women on hormone replacement therapy with documented serum follicle stimulating hormone level = 35 mIU/mL].

2. Women with a positive pregnancy test or who are pregnant or breastfeeding.

3. The subject has a current diagnosis of psychotic disorder such as bipolar disorder, schizophrenia, or depression.

4. The subject is currently diagnosed with another disorder on the autism spectrum, including Pervasive Developmental Disorder-Not Otherwise Specified, Asperger's Disorder, Rett's Disorder, Childhood Disintegrative Disorder or Fragile-X Syndrome.

5. The subject has a history of neuroleptic malignant syndrome.

6. The subject represents a significant risk of committing suicide based on history or routine psychiatric status examination.

7. The subject has had a seizure in the past year or the electroencephalograph examination is epileptiform discharge at screening.

8. The subject has a history of severe head trauma or stroke;

9. The subject has a history or current evidence of any unstable medical conditions (eg. history of congenital heart disease or arrhythmia, or cancer) that, in the judgment of the investigator would expose them to undue risk of a significant adverse event (AE) or interfere with assessments of safety or efficacy during the course of the trial.

10. Non-pharmacological therapy (e.g., psychotherapy, behavior modification, and education training, etc.) could not be stable prior to screening and consistent throughout the study, and the subject who needs to use acupuncture and moxibustion, auditory integration, biofeedback and transcranial magnetic stimulation therapy as supplemental replacement therapy in 7 days prior to taking investigational product or during the course of the trial.

11. The subject is considered treatment resistant to antipsychotics medication, in the opinion of the Investigator, based on lack of therapeutic response to 2 different antipsychotics with reasonable doses after treatment of at least 3 weeks each.

12. The subjects considered treatment resistant to aripiprazole in the opinion of the investigator based on lack of therapeutic response to an adequate dose and duration of aripiprazole treatment.

13. The following laboratory test results, vital sign and Electrocardiograph (ECG) findings are exclusionary:

• QTc > 450 msec (male), QTc > 470 msec (female)

• Platelets (below the lower limit)

• Hemoglobin (below the lower limit)

• Neutrophils (below the lower limit)

• AST (SGOT) or ALT (SGPT) (above the upper limit)

• Creatinine (above the upper limit) In addition, subjects should be excluded if they have any other abnormal laboratory test result, vital sign result or ECG finding that in the investigator's judgment is clinically significant, in that it would impact the safety of the patient or the interpretation of the study results.

14. The subject weighs < 15 kg.

15. The subject has a known allergy or hypersensitivity to aripiprazole or other dihydrocarbostyrils (eg. carteolol, vesnarinone, and cilostazol).

16. The subject has participated in any clinical trials with an investigational agent within the past month.

17. Subjects who are likely to require prohibited concomitant therapy during the trial (refer to Section 7 Prohibited and Restricted Therapies).

18. Subjects who participated in a previous clinical trial of aripiprazole (with the exception of Investigator Sponsored Trials).

Related Conditions & MeSH terms

• Autistic Disorder

Intervention

Drug:
• Aripiprazole Oral Solution
Aripiprazole 2~15 mg/day (2~15 mL/day)
• Placebo Oral Solution
Placebo 2~15 mg/day (2~15 mL/day)

Locations

Country	Name	City	State
China	6th affiliated hospital, Peking University	Beijing	Beijing

Sponsors (1)

Lead Sponsor	Collaborator
Otsuka Beijing Research Institute

Country where clinical trial is conducted

China, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Changes from Baseline to Week 8 (or endpoint) in the ABC-I score	The objective of the primary analysis is to compare the efficacy of aripiprazole flexible-dosed (2 ~ 15 mg/day) with placebo in reducing serious behavioral problems, specifically irritability, agitation and self-injurious behavior, in children and adolescents with a diagnosis of Autistic Disorder. The efficacy is assessed by assessed by change from baseline to endpoint on the Irritability Subscale of the ABC (ABC-I).	Baseline and 8 weeks (or endpoint)
Secondary	Clinician-rated CGI-I score at Week 8 (or endpoint)	The efficacy is assessed by the clinician-rated CGI-I score at Week 8	Baseline and 8 weeks (or endpoint)
Secondary	Change in ABC subscale scores from Baseline to Week 8 (or endpoint)	The efficacy is assessed by changes from Baseline to Week 8 (or endpoint) in Social Withdrawal, Hyperactivity, Stereotypy and Inappropriate Speech Subscale scores of the ABC	Baseline and 8 weeks (or endpoint)
Secondary	Response Rate at Week 8 (or endpoint) (or endpoint)	The response is defined as a reduction =25% in ABC-I score compared to the baseline, and a CGI-I score of much improved or very much improved) at Week 8 (or endpoint).The efficacy is assessed by response rate at Week 8 (or endpoint).	Baseline and 8 weeks (or endpoint)